English
Regional settings| Spread | 0.06 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 1.84 |
| Open | 1.84 |
| 1-Year Change | 234.55% |
| Day's Range | 1.8 - 1.84 |
Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the drug discovery and development of Synthetic Biotic medicines. Its product pipeline includes Synthetic Biotic medicines for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria. The Company's lead product candidate includes SYNB1618, which is an oral therapy for the treatment of PKU. Its other product candidate SYNB8802 is developed for the treatment of Enteric Hyperoxaluria. The Company developed Synthetic Biotic medicines to treat certain cancers that are designed to modify the tumor microenvironment, activate the immune system and result in tumor reduction. It is developing SYNB1891 for the treatment solid tumors and lymphoma. The Company is conducting Phase II clinical trial with SYNB1618.
BRIEF: For the fiscal year ended 31 December 2021, Synlogic Inc revenues increased from $545K to $1.8M. Net loss increased 2% to $60.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - Balancing increase of 18% to $13.4M (expense), Interest and investment income decrease of 84% to $210K (income).
